Interventions for convergence insufficiency: a network meta-analysis.
Journal
The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747
Informations de publication
Date de publication:
02 12 2020
02 12 2020
Historique:
entrez:
2
12
2020
pubmed:
3
12
2020
medline:
16
1
2021
Statut:
epublish
Résumé
Convergence insufficiency is a common binocular vision disorder in which the eyes have a strong tendency to drift outward (exophoria) with difficulty turning the eyes inward when reading or doing close work. To assess the comparative effectiveness and relative ranking of non-surgical interventions for convergence insufficiency through a systematic review and network meta-analysis (NMA). We searched CENTRAL, MEDLINE, Embase, PubMed and three trials registers up to 20 September 2019. We included randomized controlled trials (RCTs) examining any form of non-surgical intervention versus placebo, no treatment, sham treatment, or other non-surgical interventions. Participants were children and adults with symptomatic convergence insufficiency. We followed standard Cochrane methodology. We performed NMAs separately for children and adults. We included 12 trials (six in children and six in adults) with a total of 1289 participants. Trials evaluated seven interventions: 1) office-based vergence/accommodative therapy with home reinforcement; 2) home-based pencil/target push-ups; 3) home-based computer vergence/accommodative therapy; 4) office-based vergence/accommodative therapy alone; 5) placebo vergence/accommodative therapy or other placebo intervention; 6) prism reading glasses; and 7) placebo reading glasses. Six RCTs in the pediatric population randomized 968 participants. Of these, the Convergence Insufficiency Treatment Trial (CITT) Investigator Group completed four RCTs with 737 participants. All four CITT RCTs were rated at low risk of bias. Diagnostic criteria and outcome measures were identical or similar among these trials. The four CITT RCTs contributed data to the pediatric NMA, incorporating interventions 1, 2, 3 and 5. When treatment success was defined by a composite outcome requiring both clinical measures of convergence to be normal, and also show a pre-specified magnitude of improvement, we found high-certainty evidence that office-based vergence/accommodative therapy with home reinforcement increases the chance of a successful outcome, compared with home-based computer vergence/accommodative therapy (risk ratio (RR) 1.96, 95% confidence interval (CI) 1.32 to 2.94), home-based pencil/target push-ups (RR 2.86, 95% CI 1.82 to 4.35); and placebo (RR 3.04, 95% CI 2.32 to 3.98). However, there may be no evidence of any treatment difference between home-based computer vergence/accommodative therapy and home-based pencil/target push-ups (RR 1.44, 95% CI 0.93 to 2.24; low-certainty evidence), or between either of the two home-based therapies and placebo therapy, for the outcome of treatment success. When treatment success was defined as the composite convergence and symptom success outcome, we found moderate-certainty evidence that participants who received office-based vergence/accommodative therapy with home reinforcement were 5.12 (95% CI 2.01 to 13.07) times more likely to achieve treatment success than those who received placebo therapy. We found low-certainty evidence that participants who received office-based vergence/accommodative therapy with home reinforcement might be 4.41 (95% CI 1.26 to 15.38) times more likely to achieve treatment success than those who received home-based pencil push-ups, and 4.65 (95% CI 1.23 to 17.54) times more likely than those who received home-based computer vergence/accommodative therapy. There was no evidence of any treatment difference between home-based pencil push-ups and home-based computer vergence/accommodative therapy, or between either of the two home-based therapies and placebo therapy. One RCT evaluated the effectiveness of base-in prism reading glasses in children. When base-in prism reading glasses were compared with placebo reading glasses, investigators found no evidence of a difference in the three outcome measures of near point convergence (NPC), positive fusional vergence (PFV), or symptom scores measured by the Convergence Insufficiency Symptom Survey (CISS). Six RCTs in the adult population randomized 321 participants. We rated only one RCT at low risk of bias. Because not all studies of adults included composite success data, we could not conduct NMAs for treatment success. We thus were limited to comparing the mean difference (MD) between interventions for improving NPC, PFV, and CISS scores individually using data from three RCTs (107 participants; interventions 1, 2, 4 and 5). Compared with placebo treatment, office-based vergence accommodative therapy was relatively more effective in improving PFV (MD 16.73, 95% CI 6.96 to 26.60), but there was no evidence of a difference for NPC or the CISS score. There was no evidence of difference for any other comparisons for any outcomes. One trial evaluated base-in prism glasses prescribed for near-work activities and found that the prism glasses group had fewer symptoms compared with the placebo glasses group at three months (MD -8.9, 95% CI -11.6 to -6.3). The trial found no evidence of a difference with this intervention in NPC or PFV. No adverse effects related to study treatments were reported for any of the included studies. Excellent adherence was reported for office-based vergence/accommodative therapy (96.6% or higher) in two trials. Reported adherence with home-based therapy was less consistent, with one study reporting decreasing adherence over time (weeks 7 to 12) and lower completion rates with home-based pencil/target push-ups. Current research suggests that office-based vergence/accommodative therapy with home reinforcement is more effective than home-based pencil/target push-ups or home-based computer vergence/accommodative therapy for children. In adults, evidence of the effectiveness of various non-surgical interventions is less clear.
Sections du résumé
BACKGROUND
Convergence insufficiency is a common binocular vision disorder in which the eyes have a strong tendency to drift outward (exophoria) with difficulty turning the eyes inward when reading or doing close work.
OBJECTIVES
To assess the comparative effectiveness and relative ranking of non-surgical interventions for convergence insufficiency through a systematic review and network meta-analysis (NMA).
SEARCH METHODS
We searched CENTRAL, MEDLINE, Embase, PubMed and three trials registers up to 20 September 2019.
SELECTION CRITERIA
We included randomized controlled trials (RCTs) examining any form of non-surgical intervention versus placebo, no treatment, sham treatment, or other non-surgical interventions. Participants were children and adults with symptomatic convergence insufficiency.
DATA COLLECTION AND ANALYSIS
We followed standard Cochrane methodology. We performed NMAs separately for children and adults.
MAIN RESULTS
We included 12 trials (six in children and six in adults) with a total of 1289 participants. Trials evaluated seven interventions: 1) office-based vergence/accommodative therapy with home reinforcement; 2) home-based pencil/target push-ups; 3) home-based computer vergence/accommodative therapy; 4) office-based vergence/accommodative therapy alone; 5) placebo vergence/accommodative therapy or other placebo intervention; 6) prism reading glasses; and 7) placebo reading glasses. Six RCTs in the pediatric population randomized 968 participants. Of these, the Convergence Insufficiency Treatment Trial (CITT) Investigator Group completed four RCTs with 737 participants. All four CITT RCTs were rated at low risk of bias. Diagnostic criteria and outcome measures were identical or similar among these trials. The four CITT RCTs contributed data to the pediatric NMA, incorporating interventions 1, 2, 3 and 5. When treatment success was defined by a composite outcome requiring both clinical measures of convergence to be normal, and also show a pre-specified magnitude of improvement, we found high-certainty evidence that office-based vergence/accommodative therapy with home reinforcement increases the chance of a successful outcome, compared with home-based computer vergence/accommodative therapy (risk ratio (RR) 1.96, 95% confidence interval (CI) 1.32 to 2.94), home-based pencil/target push-ups (RR 2.86, 95% CI 1.82 to 4.35); and placebo (RR 3.04, 95% CI 2.32 to 3.98). However, there may be no evidence of any treatment difference between home-based computer vergence/accommodative therapy and home-based pencil/target push-ups (RR 1.44, 95% CI 0.93 to 2.24; low-certainty evidence), or between either of the two home-based therapies and placebo therapy, for the outcome of treatment success. When treatment success was defined as the composite convergence and symptom success outcome, we found moderate-certainty evidence that participants who received office-based vergence/accommodative therapy with home reinforcement were 5.12 (95% CI 2.01 to 13.07) times more likely to achieve treatment success than those who received placebo therapy. We found low-certainty evidence that participants who received office-based vergence/accommodative therapy with home reinforcement might be 4.41 (95% CI 1.26 to 15.38) times more likely to achieve treatment success than those who received home-based pencil push-ups, and 4.65 (95% CI 1.23 to 17.54) times more likely than those who received home-based computer vergence/accommodative therapy. There was no evidence of any treatment difference between home-based pencil push-ups and home-based computer vergence/accommodative therapy, or between either of the two home-based therapies and placebo therapy. One RCT evaluated the effectiveness of base-in prism reading glasses in children. When base-in prism reading glasses were compared with placebo reading glasses, investigators found no evidence of a difference in the three outcome measures of near point convergence (NPC), positive fusional vergence (PFV), or symptom scores measured by the Convergence Insufficiency Symptom Survey (CISS). Six RCTs in the adult population randomized 321 participants. We rated only one RCT at low risk of bias. Because not all studies of adults included composite success data, we could not conduct NMAs for treatment success. We thus were limited to comparing the mean difference (MD) between interventions for improving NPC, PFV, and CISS scores individually using data from three RCTs (107 participants; interventions 1, 2, 4 and 5). Compared with placebo treatment, office-based vergence accommodative therapy was relatively more effective in improving PFV (MD 16.73, 95% CI 6.96 to 26.60), but there was no evidence of a difference for NPC or the CISS score. There was no evidence of difference for any other comparisons for any outcomes. One trial evaluated base-in prism glasses prescribed for near-work activities and found that the prism glasses group had fewer symptoms compared with the placebo glasses group at three months (MD -8.9, 95% CI -11.6 to -6.3). The trial found no evidence of a difference with this intervention in NPC or PFV. No adverse effects related to study treatments were reported for any of the included studies. Excellent adherence was reported for office-based vergence/accommodative therapy (96.6% or higher) in two trials. Reported adherence with home-based therapy was less consistent, with one study reporting decreasing adherence over time (weeks 7 to 12) and lower completion rates with home-based pencil/target push-ups.
AUTHORS' CONCLUSIONS
Current research suggests that office-based vergence/accommodative therapy with home reinforcement is more effective than home-based pencil/target push-ups or home-based computer vergence/accommodative therapy for children. In adults, evidence of the effectiveness of various non-surgical interventions is less clear.
Identifiants
pubmed: 33263359
doi: 10.1002/14651858.CD006768.pub3
pmc: PMC8092638
doi:
Banques de données
ClinicalTrials.gov
['NCT03431454', 'NCT00347581', 'NCT00347945', 'NCT00338611', 'NCT02207517', 'NCT01515943']
Types de publication
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
CD006768Subventions
Organisme : NEI NIH HHS
ID : UG1 EY020522
Pays : United States
Organisme : NEI NIH HHS
ID : U01 EY020522
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY011756
Pays : United States
Commentaires et corrections
Type : UpdateOf
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Références
Am J Optom Physiol Opt. 1986 Apr;63(4):244-51
pubmed: 3706478
J Am Optom Assoc. 1977 Aug;48(8):1035-9
pubmed: 893946
Int Ophthalmol. 2017 Oct;37(5):1139-1146
pubmed: 27770391
PLoS Med. 2020 Apr 3;17(4):e1003082
pubmed: 32243458
Front Hum Neurosci. 2015 Jul 27;9:419
pubmed: 26283944
Optom Vis Sci. 2009 Sep;86(9):1096-103
pubmed: 19668097
J Rehabil Res Dev. 2014;51(2):175-91
pubmed: 24933717
Eye (Lond). 2018 Apr;32(4):693-700
pubmed: 29271419
Optom Vis Sci. 2017 Jan;94(1):74-88
pubmed: 27464574
J Neuroophthalmol. 2018 Jun;38(2):230-236
pubmed: 28059865
Am J Optom Arch Am Acad Optom. 1971 May;48(5):373-6
pubmed: 4931926
Optom Vis Sci. 2002 Apr;79(4):265-7
pubmed: 11999152
J Ophthalmol. 2016;2016:6963976
pubmed: 27525112
Optom Vis Sci. 2009 Feb;86(2):153-6
pubmed: 19156012
Transl Vis Sci Technol. 2016 Mar 11;5(2):8
pubmed: 26981330
Ophthalmic Physiol Opt. 2020 Jan;40(1):8-16
pubmed: 31797407
Optom Vis Sci. 2018 Jun;95(6):505-514
pubmed: 29787484
Optom Vis Sci. 2002 Mar;79(3):151-7
pubmed: 11913841
Ophthalmic Physiol Opt. 2014 Mar;34(2):250-62
pubmed: 24471739
Science. 1988 Nov 4;242(4879):728-35
pubmed: 3055293
Vision Res. 2018 Aug;149:59-65
pubmed: 29940191
Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2560-6
pubmed: 19151384
Optom Vis Sci. 2019 Nov;96(11):825-835
pubmed: 31651593
J Optom. 2017 Jul - Sep;10(3):169-175
pubmed: 28126262
Strabismus. 2005 Dec;13(4):163-8
pubmed: 16361187
Optom Vis Sci. 2009 May;86(5):420-8
pubmed: 19319008
Open Ophthalmol J. 2018 Feb 28;12:12-18
pubmed: 29541278
Br J Ophthalmol. 2014 Oct;98(10):1409-13
pubmed: 24842862
J Rehabil Res Dev. 2013;50(9):1223-40
pubmed: 24458963
Optom Vis Sci. 2016 Dec;93(12):1457-1465
pubmed: 27575992
Optometry. 2012 Apr 30;83(4):137-58
pubmed: 23231437
Am J Optom Physiol Opt. 1988 Jan;65(1):8-13
pubmed: 3348354
Am J Optom Physiol Opt. 1988 Jun;65(6):448-54
pubmed: 3046363
Vision Res. 2013 Jul 19;87:22-9
pubmed: 23694682
Optom Vis Sci. 1999 Sep;76(9):643-9
pubmed: 10498006
Am Orthopt J. 2015;65:99-103
pubmed: 26564934
Optom Vis Sci. 2018 Aug;95(8):632-642
pubmed: 30063662
Am J Optom Physiol Opt. 1987 Feb;64(2):83-9
pubmed: 3826293
Pediatr Clin North Am. 2014 Jun;61(3):621-30
pubmed: 24852157
Ophthalmic Physiol Opt. 2006 Nov;26(6):555-65
pubmed: 17040419
Optom Vis Sci. 2012 Oct;89(10):1512-20
pubmed: 22922781
Am J Optom Physiol Opt. 1979 Jan;56(1):18-22
pubmed: 484699
Vision Res. 2015 Jun;111(Pt A):105-13
pubmed: 25891521
Optom Vis Sci. 1998 Jul;75(7):506-12
pubmed: 9703039
J Clin Epidemiol. 1997 Jun;50(6):683-91
pubmed: 9250266
Curr Opin Ophthalmol. 2018 Sep;29(5):401-406
pubmed: 29994854
Cochrane Database Syst Rev. 2013 May 31;(5):CD003737
pubmed: 23728647
Br J Oral Maxillofac Surg. 1995 Apr;33(2):71-5
pubmed: 7772590
Optom Vis Sci. 2009 Apr;86(4):357-63
pubmed: 19289977
J AAPOS. 2011 Apr;15(2):140-3
pubmed: 21458340
Res Synth Methods. 2012 Jun;3(2):80-97
pubmed: 26062083
Middle East Afr J Ophthalmol. 2015 Jan-Mar;22(1):97-102
pubmed: 25624682
Optom Vis Sci. 2010 Dec;87(12):E985-1002
pubmed: 21057347
Am Orthopt J. 2014;64:112-6
pubmed: 25313120
Optometry. 2009 Dec;80(12):702-16
pubmed: 19932444
Strabismus. 2014 Dec;22(4):147-51
pubmed: 25333204
Ophthalmic Epidemiol. 2008 Jan-Feb;15(1):24-36
pubmed: 18300086
Optom Vis Sci. 2003 Dec;80(12):832-8
pubmed: 14688547
Br J Ophthalmol. 2005 Oct;89(10):1318-23
pubmed: 16170124
Invest Ophthalmol Vis Sci. 2006 Jul;47(7):2876-80
pubmed: 16799027
J Pediatr Ophthalmol Strabismus. 2005 Mar-Apr;42(2):82-8
pubmed: 15825744
Med Glas (Zenica). 2012 Aug;9(2):293-8
pubmed: 22926366
Ophthalmologe. 2002 Jan;99(1):3-9
pubmed: 11840793
J Am Optom Assoc. 1999 Apr;70(4):225-32
pubmed: 10457698
J Ophthalmic Vis Res. 2018 Jul-Sep;13(3):307-314
pubmed: 30090188
Optometry. 2002 Dec;73(12):735-62
pubmed: 12498561
J Am Optom Assoc. 1988 Jun;59(6):440-5
pubmed: 3403888
Optometry. 2009 Sep;80(9):481-6
pubmed: 19716076
Clin Exp Optom. 2019 Mar;102(2):166-171
pubmed: 30206993
Am Orthopt J. 2013;63:32-35
pubmed: 24260806
Ophthalmic Physiol Opt. 2006 Nov;26(6):587-96
pubmed: 17040423
J AAPOS. 2015 Oct;19(5):417-21
pubmed: 26486022
Front Integr Neurosci. 2014 Jun 17;8:50
pubmed: 24987340
Oftalmologia. 2001;53(3):66-9
pubmed: 11915694
Clin Exp Optom. 2017 Nov;100(6):642-648
pubmed: 27859646
J Optom. 2018 Jan - Mar;11(1):40-48
pubmed: 28599912
Klin Monbl Augenheilkd. 1994 Aug;205(2):70-5
pubmed: 7967409
Optom Vis Sci. 2003 Mar;80(3):214-25
pubmed: 12637833
Ophthalmic Physiol Opt. 2004 Sep;24(5):384-90
pubmed: 15315652
J Optom. 2016 Oct-Dec;9(4):246-57
pubmed: 26750804
Arch Ophthalmol. 2005 Jan;123(1):14-24
pubmed: 15642806
Cochrane Database Syst Rev. 2011 Mar 16;(3):CD006768
pubmed: 21412896
Am J Optom Physiol Opt. 1986 Aug;63(8):587-609
pubmed: 3532810
Am Orthopt J. 2013;63:36-40
pubmed: 24260807
Binocul Vis Strabismus Q. 2002;17(2):135-42
pubmed: 12067271
J Med Libr Assoc. 2006 Apr;94(2):130-6
pubmed: 16636704
Optom Vis Sci. 1997 Feb;74(2):111-3
pubmed: 9097328
Annu Int Conf IEEE Eng Med Biol Soc. 2019 Jul;2019:104-109
pubmed: 31945855
J AAPOS. 2014 Apr;18(2):162-8
pubmed: 24582466
Int J Epidemiol. 2013 Feb;42(1):332-45
pubmed: 23508418
Strabismus. 2017 Sep;25(3):101-111
pubmed: 28414562
Am J Optom Physiol Opt. 1982 Dec;59(12):983-6
pubmed: 7158656
Clin Exp Optom. 2012 Mar;95(2):192-7
pubmed: 22233325
Optom Vis Sci. 2005 Jul;82(7):583-95
pubmed: 16044063
PLoS One. 2014 Jul 03;9(7):e99682
pubmed: 24992266
Arch Ophthalmol. 2008 Oct;126(10):1336-49
pubmed: 18852411
PLoS One. 2013 Oct 03;8(10):e76654
pubmed: 24098547
J Atten Disord. 2016 Oct;20(10):836-44
pubmed: 24271946
Optom Vis Sci. 1998 Oct;75(10):731-42
pubmed: 9798213
Optom Vis Sci. 2017 Jan;94(1):68-73
pubmed: 27505624